22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Nordic M&A activity has staged something of a comeback. Q2 2019 witnessed a sharp quarter-on-quarter...
Read More >
The U.S. Department of Labor’s Mine Safety and Health Administration (MSHA) announced today that it...
Read More >
All of our workplaces are vulnerable to their own Mind Flayer, though. It may be a grievance among e...
Read More >
The Department of Labor’s Wage and Hour Division (WHD) released Letter CCPA2019-l on September 10, ...
Read More >
A survey of the country’s most powerful CEOs by the Business Roundtable shows an interesting shift ...
Read More >
The European Green Deal is a new growth strategy invented to reshape the EU economy. In the eyes of ...
Read More >